drugset / Trial / NCT04635605

Methylene Blue Treatment of COVID-19

NCT04635605

Phase 2 Completed 29 enrolled Fondazione Epatocentro Ticino
RandomizedParallel-groupTriple-blindTreatment

Summary

Despite enormous progress in understanding COVID-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved. Repurposing of well known, widely available drugs represent an attractive approach to speed up availability of active treatments. Such substances as i.e. hydroxychloroquine and others, are already under investigation and in widespread off label use. For many reasons Methylene blue (MB), the oldest synthetic substance in medicine (1876 synthesized by BASF) is such a promising candidate for an active treatment against SARS-CoV-2 infected people and for COVID-19 patients.

Timeline

Start
2020-11-05
Primary completion
2021-08-13
Completion
2021-08-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 100 mg Oral

Indications